logo
GenAI job postings rise across Europe: Which countries lead the way?

GenAI job postings rise across Europe: Which countries lead the way?

Yahooa day ago

Recent figures reveal a sharp rise in the share of job postings mentioning generative AI (GenAI) over the past two years across Europe, North America, and Australia.
'Nearly every job will be impacted by AI (artificial intelligence) at some point,' said Pawel Adrjan, Director of Economic Research at Indeed.
In major European economies, the share of GenAI-related job postings more than doubled in the 12 months to March 2025, according to the global hiring platform Indeed.
GenAI jobs refer to roles involving the development, implementation, or oversight of generative artificial intelligence technologies.
This could include positions building GenAI features, or roles leveraging this tech to create more efficient processes such as reviewing data, summarising reports, or drafting written or creative materials.
Ireland is leading the way by a significant extent in Europe when it comes to these kinds of jobs. Indeed data shows that, as of 31 March 2025, more than 0.7% of Irish job postings include terms related to GenAI.
This is an increase of 204%, with the share more than tripling in just one year. The figure was only 0.02% in the same period in 2023, highlighting a tremendous rise over the past two years.
For comparison, job openings in Ireland for chefs currently represent 1.1% of total postings. Opportunities for lorry drivers and bartenders represent 0.8% and 0.6% respectively.
These figures highlight Ireland's position at the forefront of digital innovation in the European labour market.
"Ireland's leading presence in GenAI job postings reflects the country's well-established technology sector and its role as a European base for many global firms,' Pawel Adrjan told Euronews Business.
'With a high concentration of tech employers, including major multinationals and a number of start-ups, it's natural we would see a proportionate increase in GenAI roles there too,' he added.
Globally recognised names such as Alphabet, Amazon, Apple, Meta, IBM, Intel, Microsoft, Oracle, Salesforce, and Tencent, among many others, have established significant European operations in Ireland.
Adrjan of Indeed also noted that the steady growth in AI-related roles is also indicative of Ireland's focus on industries like software, financial services, and life sciences, which are increasingly integrating AI tools into their operations.
Several major EU and international markets — including Germany, France, Australia, the US, the UK, and Canada — lag behind Ireland in incorporating GenAI into job roles. In each of these countries, the share of job postings mentioning GenAI remains at or below 0.3% as of late March 2025.
However, the share has risen by around 100% or more in these European countries over the past year. This highlights how the job market is evolving, even if still well behind Ireland's 204% increase.
Related
Highest-paying jobs in Germany: Official data and job postings reveal top salaries
Jobs market at a crossroads: Which are the fastest growing and declining jobs?
The UK has the highest share of GenAI-related job postings among the three largest European economies, at 0.33% as of 31 March 2025. That's up 120% from 0.15% the previous year.
Germany follows with 0.23% (a 109% annual increase), and France at 0.21% (a 91% increase).
GenAI jobs appear across a range of categories. Among the top occupations in Ireland where job postings mention GenAI, mathematics leads by a wide margin. As of March 2025, 14.7% of advertised roles in mathematics referenced GenAI, significantly higher than any other category. This was followed by software development (4.9%), media & communications (3.9%), architecture (2.4%), and scientific research & development (2.1%).
Other fields showing notable GenAI activity include industrial engineering (1.8%), legal (1.7%), marketing (1.6%), medical information (1.5%), and production & manufacturing (0.9%).
Pawel Adrjan explained that in many developed markets, ageing populations are contributing to labour shortages and widening skills gaps. As a result, employers face growing competition for talent and are increasingly turning to skills-first hiring approaches, including the use of AI to expand and enhance their workforce.
While nearly every job will be impacted by AI at some point, Adrjan emphasised that human intelligence remains a key requirement.
'We know that GenAI tools are an excellent resource to enhance efficiencies, but they are currently limited in comparison to human expertise,' he said.
Joint research by Indeed and the World Economic Forum earlier this year showed that humans will remain an essential part of the global workforce as AI continues to evolve.
Indeed analysed over 2,800 work-related skills to assess GenAI's potential to substitute employees. The findings show that around two-thirds (69%) are unlikely to be replaced by GenAI, underscoring the continued importance of human expertise in the workplace.
The chart above shows the likelihood of certain skills to be replaced or substituted by GenAI. They are ranked from 'very low capacity' (hard to replace) to 'high capacity' (easy to replace).
AI and Big Data, as well as reading, writing, and mathematics are on the 'high capacity' side of the scale. On the 'very low capacity' side of the scale, we can see sensory-processing abilities, along with empathy and active listening.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Yahoo

time23 minutes ago

  • Yahoo

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

2026 Ram 2500 Warlock Is a HD Off-Road Truck That's Affordable
2026 Ram 2500 Warlock Is a HD Off-Road Truck That's Affordable

Car and Driver

time40 minutes ago

  • Car and Driver

2026 Ram 2500 Warlock Is a HD Off-Road Truck That's Affordable

The 2026 Ram 2500 lineup adds two new value-minded models: the Black Express and the Warlock. The Warlock starts at $57,165 and includes 34-inch-tall all-terrain tires, an off-road-tuned suspension, unique visual add-ons, and cloth bench seats. The Black Express starts at $53,735 and comes with black 20-inch wheels, a sporty hood, body-colored bumpers, and tubular side steps. Truck makers have the most creative names for their off-road-focused pickups. Chevy's Trail Boss and Ford's Tremor treatments immediately spring to mind, and Ram offers the Rebel. For the 2026 model year, Ram's heavy-duty lineup adds a Warlock trim, which is the most affordable model for those who like to go past where the blacktop ends. Warlock Helps You Save a Buck The Warlock moniker dates back to the 1970s, when it was used on the Dodge D-series trucks. More recently, it was resurrected on the Ram 1500, and it remains the best off-road value. The same is true for the first heavy-duty Warlock, which is based on the Ram 2500 Tradesman. The Warlock's only available configuration includes the crew cab and shorter cargo bed. Four-wheel drive and a 405-hp Hemi 6.4-liter V-8 are standard. It starts at $57,165, but opting for the Cummins diesel 6.7-liter straight-six is expected to add $12,595. For comparison, the Ram 2500 Rebel has a $77,015 base price ($89,610 with the Cummins), and the Hemi-only Power Wagon starts at $80,510. Ram So, what do you get with the Warlock? Every model rides on 34-inch-tall Goodyear Wrangler Duratrac all-terrain tires that are mounted on 20-inch wheels. Its suspension has been revised for dirt duty and features a set of Bilstein dampers, the transfer case has a skid plate for extra protection, and there's a limited-slip rear diff to help with low-traction situations. Warlocks can be easily identified by their bedside decals. Black bumpers, fender flares, and grille surrounds add to the rugged aesthetic. Inside, there's cloth upholstery instead of leather and an absence of high-end features, but we appreciate the bench seats An Affordable Street Truck Not everyone wants their big truck to roll on knobby tires, instead preferring a sportier look. That's where the 2026 Ram 2500 Black Express comes into play. Like the Warlock, it's based on the entry-level Tradesmen. While the crew-cab body style is mandatory, Ram lets customers choose between rear- and all-wheel drive. The former starts at $53,735, but that price is expected to rise by $12,595 for those who want the Cummins diesel. Ram Regardless of what's under the Black Express's special bulging hood, every version features black 20-inch wheels as well as bumpers and a grille surround that match the body color. Paint options include Diamond Black, Bright White, Granite Crystal, Silver Zynith, Forged Blue, Flame Red, Ceramic Grey, and Molten Red. A pair of cab-length tubular side steps helps passengers climb into the cabin. Like the Warlock, the bench seats are covered in cloth, and the floor and floor mats are carpeted. Towing mirrors and parking sensors at both ends are standard fare. The 2026 Ram 2500 Warlock and Black Express are now available to order, with the first deliveries expected to reach dealerships sometime in July through September. Eric Stafford Managing Editor, News Eric Stafford's automobile addiction began before he could walk, and it has fueled his passion to write news, reviews, and more for Car and Driver since 2016. His aspiration growing up was to become a millionaire with a Jay Leno–like car collection. Apparently, getting rich is harder than social-media influencers make it seem, so he avoided financial success entirely to become an automotive journalist and drive new cars for a living. After earning a journalism degree at Central Michigan University and working at a daily newspaper, the years of basically burning money on failed project cars and lemon-flavored jalopies finally paid off when Car and Driver hired him. His garage currently includes a 2010 Acura RDX, a manual '97 Chevy Camaro Z/28, and a '90 Honda CRX Si. Read full bio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store